AzTrials
AzTrials

Hypersensitivity, ImmediateNCT00887939

Pathogenesis of Physical Induced Urticarial Syndromes

An observational study of Hypersensitivity, Immediate and Autoinflammatory Syndromes, run by National Institute of Allergy and Infectious Diseases (NIAID) at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Background: Urticaria is a common itchy skin disorder that may occur spontaneously or on exposure to a physical trigger (called physical urticaria). Researchers are studying the genetic basis of a physically induced urticarial syndrome. Read more about this study

Who is it for?
Ages 2 to 90 years
How many people
173 participants
Where
1 siteUnited States
Study dates
17 Jun 2009to 3 Jun 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 2 to 90 years
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Primary clinical

Who may be able to join

  • Affected subjects/guardian must:
  • Be at least 2 years of age and no older than 90 years of age
  • Have a history of a physical urticaria, which has been evaluated by the patient's healthcare practitioner.
  • Provide copies of pertinent medical records and laboratory studies
  • Have a health care provider outside of NIH
  • Be willing to give informed consent
Show all 19Show fewer
  • Be willing to donate blood for sample storage to be used for future research
  • Non-affected relatives/guardian must:
  • Be at least 2 years of age and no older than 90 years of age
  • Have a relative who is enrolled on this protocol and is known to have a documented history of a physical urticaria
  • Not have a history of physical urticaria
  • Be willing to give informed consent
  • Be willing to donate blood for sample storage to be used for future research
  • Healthy volunteers must:
  • Be 18-65 years of age
  • Be non-atopic (not have a history of allergic rhinitis, asthma, atopic dermatitis) per subject medical history
  • Have the ability to give informed consent
  • Be willing to donate blood for sample storage to be used for future research
  • Not have a history of physical urticaria

Who cannot join

  • The following criteria apply to all subjects:
  • Presence of conditions which, in the judgment of the investigator or the referring physician, may put the subject at undue risk, such as acute infection, severe thrombocytopenia (minimum platelet count of 30,000), or significant cardiovascular disease
  • Any condition that in the view of the principal investigator (PI) would make the subject unsuitable for enrollment in this study
  • History of HIV or other known immunodeficiency
  • History or evidence of chronic Hepatitis B and/or C infection
  • Pregnancy

Trial locations and contacts

1 site in 1 country.

United States1 site
  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892

Other trials in United States

About this study

Official title: Pathogenesis and Genetic Basis of Physical Induced Urticarial Syndromes

Background:

  • Urticaria is a common itchy skin disorder that may occur spontaneously or on exposure to a physical trigger (called physical urticaria).
  • Researchers are studying the genetic basis of a physically induced urticarial syndrome. Once called familial cold urticaria, this condition is now called familial cold autoinflammatory syndrome (FCAS). FCAS is an autoinflammatory disease, a group of inherited disorders characterized by unprovoked episodes of inflammation. Patients with FCAS often have hives, joint pain, and fever following general exposure to cold.
  • Patients with FCAS have a mutation in a gene that makes a protein called cryopyrin. Cryopyrin seems to be involved with the production of a proinflammatory mediator called interleukin-1 (IL-1). Patients with FCAS and others with autoinflammatory syndromes have benefited from medication that blocks the effects of IL-1.
Read more

Objectives:

  • To investigate mechanisms that may cause physical hives or urticaria.
  • To reproduce urticaria through challenge testing (procedures to test the skin for a reaction to a stimulus), followed by mast cell studies, measurement of IL-1, genetic studies, and other molecular studies to lead to a better understanding of urticaria and to design safe and more effective treatments.

Eligibility:

  • Patients between 6 months and 65 years of age with a documented history of clinically reproducible physical urticaria that triggers hives and that has been evaluated by a physician. Patients should have a letter of referral, including copies of pertinent medical history and laboratory studies, from a referring physician.
  • Affected and nonaffected family members of such patients.
  • Exclusion criteria include (1) the presence of conditions that may put the subject at undue risk, such as acute infection, severe thrombocytopenia (a lower than normal number of platelets in the blood), or significant cardiovascular disease; (2) any condition that would make the subject unsuitable for enrollment in this study; and (3) a history of HIV, other known immunodeficiency, or evidence of chronic Hepatitis B and/or C infection.

Design:

  • Researchers will conduct the following tests to verify which triggers cause the hives:
  • History and physical exam to determine the relationship between the trigger and appearance of the hives.
  • Blood samples for baseline screening (additional samples may be taken within 8 hours of triggering hives).
  • Verification of hives using standard challenge testing.
  • Procedures to trigger urticaria (the challenge testing) include dermatographism (stroking the skin), delayed pressure urticaria (direct pressure), cold-induced urticaria (cold exposure), cholinergic urticaria (exercise, hot water), solar urticaria (sun exposure), localized heat urticaria (direct heat exposure), aquagenic urticaria (room temperature water), and vibratory angioedema (direct vibratory stimulus exposure).
  • Participants who have a positive history for hives and failed challenge testing (that is, hives resulted from the triggers) will be asked to provide a skin biopsy and additional bloods samples for research purposes.
  • Participants will be asked to return to the clinic within 1 month if multiple triggers could not be verified during the initial visit, or to return for additional research evaluations, which may include a skin punch biopsy and blood sample collection. Patients may have to stay at the hospital overnight, if required to document the disease.
  • Nonaffected family members who enroll in this protocol will provide samples for comparison with the family member who has a history of hives.
  • Participants will receive a small financial compensation for the skin biopsy.
Read the detailed description

Urticaria is a common skin disorder that is classified according to its chronicity into acute and chronic forms. It may occur spontaneously or on exposure to a physical factor. In the latter case, the urticaria is classified as a physical urticaria . Physical urticaria may be induced by mechanical and applied pressure, exercise, or exposure to cold, heat, sun, water, or vibration. The urticarial lesions are generally thought to be the result of mast cell activation and degranulation, which is supported by the finding of increased levels of serum histamine during some urticarial flares. Passive transfer experiments, whereupon serum from affected donors is transferred into recipient s skin followed by physical stimulation with resultant urticaria at the site of challenge, have been positive in some instances. This suggests the presence of an intrinsic factor in serum, such as IgE, which then mediates activation of tissue mast cells. However, the pathogenesis in general remains unclear and a genetic basis for these disorders has not been elucidated.

The goal of this protocol is thus to gain a better understanding of the pathogenesis of physical urticaria through the investigation of subjects with severe and unusual phenotypes and/or inherited patterns of disease. Subjects will undergo a clinical evaluation that will include verification of their urticaria. Blood and tissue samples, if available, will be collected for analysis. The analysis will be targeted toward the determination of novel serum mediators, mast cell activation and mutational analysis in families with inherited patterns.

Keywords
Hives, Inflammasome, Mast Cell, Natural History, Urticaria
Medical subject headings
Hypersensitivity, Immediate, Familial dermographism, Cryopyrin-Associated Periodic Syndromes, Urticaria

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT00887939
Study groupRoleWhat they receive
1Affected physical urticaria
2Healthy volunteer
3Unaffected relative

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. to determine the role of mast cell activation and genetic predisposition in the pathogenesis of physically induced urticaria.

    The patient s physical urticaria will be verified through standard testing.

    Measured: 12/31/2028

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Apr 2009 (estimated)
  2. Study start17 Jun 2009
  3. Primary completion3 Jun 2024
  4. Study completion3 Jun 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
173 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00887939
Sponsor's protocol ID
090126
Other IDs
09-I-0126
Status last verified
Mar 2026
First submitted
23 Apr 2009
Last updated
30 Mar 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: IDP will not be shared since sequencing is performed through NIH Centralized sequencing.

Publications

  • Meyer J, Gorbach AM, Liu WM, Medic N, Young M, Nelson C, Arceo S, Desai A, Metcalfe DD, Komarow HD. Mast cell dependent vascular changes associated with an acute response to cold immersion in primary contact urticaria. PLoS One. 2013;8(2):e56773. doi: 10.1371/journal.pone.0056773. Epub 2013 Feb 22.

    PubMed 23451084
  • Boyden SE, Desai A, Cruse G, Young ML, Bolan HC, Scott LM, Eisch AR, Long RD, Lee CC, Satorius CL, Pakstis AJ, Olivera A, Mullikin JC, Chouery E, Megarbane A, Medlej-Hashim M, Kidd KK, Kastner DL, Metcalfe DD, Komarow HD. Vibratory Urticaria Associated with a Missense Variant in ADGRE2. N Engl J Med. 2016 Feb 18;374(7):656-63. doi: 10.1056/NEJMoa1500611. Epub 2016 Feb 3.

    PubMed 26841242

Questions about this trial

What is this clinical trial studying?

An observational study of Hypersensitivity, Immediate and Autoinflammatory Syndromes, run by National Institute of Allergy and Infectious Diseases (NIAID) at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 19 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

to determine the role of mast cell activation and genetic predisposition in the pathogenesis of physically induced urticaria. (time frame: 12/31/2028). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00887939, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in